Veloxis Pharmaceuticals to Present Results from a Patient Subgroup Analysis of Once-Daily LCP-Tacro(tm) in Stable African-American Kidney Transplant Patients at American Transplant Congress (ATC)

Additional Presentations at ATC Will Provide Supporting Evidence of the Activity and Tolerability of LCP-Tacro in Kidney and Liver Transplant Patients HORSHOLM, Denmark, May 31, 2012 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that a subgroup analysis of African-American stable kidney transplant patients enrolled in Study 3001, a Phase 3 non-inferiority study, suggests that these patients may be safely converted from twice-daily Prograf ® to once-daily LCP-Tacr...continued VOXPY

URL: http://www.investorpoint.com/news/INTHPINK/51695916/